IN2012DN03093A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03093A
IN2012DN03093A IN3093DEN2012A IN2012DN03093A IN 2012DN03093 A IN2012DN03093 A IN 2012DN03093A IN 3093DEN2012 A IN3093DEN2012 A IN 3093DEN2012A IN 2012DN03093 A IN2012DN03093 A IN 2012DN03093A
Authority
IN
India
Prior art keywords
construct
host cell
protease
precursor protein
capsid precursor
Prior art date
Application number
Other languages
English (en)
Inventor
Charleston Bryan
Jones Ian
Original Assignee
Pirbright Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pirbright Inst filed Critical Pirbright Inst
Publication of IN2012DN03093A publication Critical patent/IN2012DN03093A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN3093DEN2012 2009-10-20 2010-09-24 IN2012DN03093A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0918375.7A GB0918375D0 (en) 2009-10-20 2009-10-20 Construct
PCT/GB2010/001807 WO2011048353A2 (en) 2009-10-20 2010-09-24 Construct

Publications (1)

Publication Number Publication Date
IN2012DN03093A true IN2012DN03093A (de) 2015-09-18

Family

ID=41462637

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3093DEN2012 IN2012DN03093A (de) 2009-10-20 2010-09-24

Country Status (16)

Country Link
US (1) US9243230B2 (de)
EP (1) EP2491118B1 (de)
JP (1) JP2013507948A (de)
KR (1) KR101818934B1 (de)
CN (1) CN102834507B (de)
AU (1) AU2010309648A1 (de)
BR (1) BR112012009475B1 (de)
CO (1) CO6551678A2 (de)
ES (1) ES2652443T3 (de)
GB (1) GB0918375D0 (de)
HU (1) HUE035889T2 (de)
IN (1) IN2012DN03093A (de)
PH (1) PH12012500662A1 (de)
RU (1) RU2565537C2 (de)
WO (1) WO2011048353A2 (de)
ZA (1) ZA201202882B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201111183D0 (en) 2011-06-30 2011-08-17 Animal Health Inst Peptide
SG11201401998VA (en) 2011-11-03 2014-05-29 Sentinext Therapeutics Sdn Bhd Vaccines directed against human enteroviruses
AU2013312971B2 (en) * 2012-09-05 2019-04-18 Medicago Inc. Picornavirus-like particle production in plants
CA2907571A1 (en) 2013-03-26 2014-10-02 The Pirbright Institute Stabilised fmdv capsids
KR20170068410A (ko) * 2014-04-29 2017-06-19 내셔날 헬스 리서치 인스티튜트 엔테로바이러스 감염증에 대항하는 아데노바이러스 벡터-기반 백신
WO2016202828A1 (en) * 2015-06-15 2016-12-22 Bavarian Nordic A/S Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
US9975926B2 (en) * 2015-12-08 2018-05-22 The United States of America, as Represented by the Secretary of Homeland Security Methods of making and using vaccines utilizing minicircle DNA expression vectors for production of foot-and-mouth-disease virus proteins and virus-like particles
US10385319B2 (en) 2016-09-08 2019-08-20 The Governement of the United States of America, as represented by the Secretary of Homeland Security Modified foot-and-mouth disease virus 3C proteases, compositions and methods thereof
US10435695B2 (en) 2016-09-08 2019-10-08 The Government of the United States of America, as represented by the Secretary of Homeland Security Fusion protein comprising Gaussia luciferase, translation interrupter sequence, and interferon amino acid sequences
US10308927B2 (en) * 2017-01-17 2019-06-04 The United States of America, as Represented by the Secretary of Homeland Security Processing of a modified foot-and-mouth disease virus P1 polypeptide by an alternative protease
WO2019092027A1 (en) * 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
GB201812474D0 (en) 2018-07-31 2018-09-12 Autolus Ltd Nucleic acid construct
WO2020067027A1 (ja) * 2018-09-28 2020-04-02 一般財団法人阪大微生物病研究会 Vlp発現cho細胞株の構築
JP2023549461A (ja) 2020-10-22 2023-11-27 インターベット インターナショナル ベー. フェー. バキュロウイルス発現ベクター
AR123873A1 (es) 2020-10-22 2023-01-18 Intervet Int Bv Vector de expresión de baculovirus
IL310905A (en) 2021-08-20 2024-04-01 Intervet Int Bv A method for producing a virus-like particle for foot-and-mouth disease virus
US20240382579A1 (en) 2021-08-20 2024-11-21 Intervet Inc. Method of producing a foot and mouth disease virus virus-like particle
WO2023020738A1 (en) 2021-08-20 2023-02-23 The Pirbright Institute Fmdv virus-like particle with double stabilizing mutation
EP4387664A1 (de) 2021-08-20 2024-06-26 Intervet International B.V. Fmdv virus-ähnliche partikel mit stabilisierender mutation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19712899C1 (de) 1997-03-27 1998-12-10 Christian Dr Probst Verfahren zur Herstellung nichtinfektiöser rekombinanter Picornavirus-Partikel
RU2143921C1 (ru) 1999-04-21 2000-01-10 Всероссийский научно-исследовательский институт защиты животных Вакцина против ящура типа а и способ ее изготовления
FR2810888B1 (fr) 2000-06-29 2004-07-30 Merial Sas Vaccin contre la fievre aphteuse
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
EP1632247A1 (de) 2004-09-03 2006-03-08 Consejo Superior De Investigaciones Cientificas Nukleinsäuren, die für FMDV Proteine kodieren und, die in virus-ähnliche Partikel assemblieren können
NZ542111A (en) 2005-08-30 2008-04-30 Otago Innovation Ltd Novel assay

Also Published As

Publication number Publication date
CN102834507B (zh) 2016-09-07
EP2491118A2 (de) 2012-08-29
EP2491118B1 (de) 2017-11-08
JP2013507948A (ja) 2013-03-07
BR112012009475B1 (pt) 2020-06-09
WO2011048353A3 (en) 2011-09-29
KR20120069756A (ko) 2012-06-28
KR101818934B1 (ko) 2018-01-17
CN102834507A (zh) 2012-12-19
CO6551678A2 (es) 2012-10-31
ES2652443T3 (es) 2018-02-02
ZA201202882B (en) 2013-06-26
HUE035889T2 (en) 2018-05-28
GB0918375D0 (en) 2009-12-02
AU2010309648A1 (en) 2012-05-03
RU2565537C2 (ru) 2015-10-20
US9243230B2 (en) 2016-01-26
PH12012500662A1 (en) 2012-10-22
US20120258133A1 (en) 2012-10-11
WO2011048353A2 (en) 2011-04-28
BR112012009475A2 (pt) 2015-09-15
RU2012120700A (ru) 2013-12-10

Similar Documents

Publication Publication Date Title
WO2011048353A3 (en) Construct for production of empty picornaviral capsids
EA201100225A1 (ru) Новые регуляторные элементы
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
MX2012007709A (es) Variantes de alfa-amilasa con estabilidad mejorada.
MY151062A (en) Pseudoinfectious flavivirus and uses thereof
MX336112B (es) Vacunas e inmunoterapicos que usan il-15 optimizada de codones y metodos para usar los mismos.
NZ597401A (en) Chimeric influenza virus-like particles comprising hemagglutinin
MX363427B (es) Mutante de epimerasa psicosa y metodo para preparar psicosa mediante el uso del mismo.
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX354704B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2012006096A (es) Polipeptidos que tienen actividad glucoamilasa y polinucleotidos que codifican para los mismos.
MX351175B (es) Detergente líquido para lavar vajillas estable al almacenamiento que contiene proteasa y amilasa.
MX350254B (es) Detergente o agente de limpieza liquido estable al almacenamiento que contiene proteasa y amilasa.
PH12014500348A1 (en) Genes and proteins for alkanoyl-coa synthesis
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
MX2014004292A (es) Variantes de glucoamilasas y polinucleotidos que las codifican.
MX369726B (es) Polipéptidos con actividad proteasa.
MX2012006095A (es) Polipeptidos que tienen actividad glucoamilasa y polinucleotidos que codifican para los mismos.
EA201201025A1 (ru) Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них
WO2013189972A3 (en) Use of polypeptides having protease activity in animal feed and detergents
EA201200186A1 (ru) Вектор, содержащий промотор маннозы, и промотор маннозы
MX2014003403A (es) Polipeptidos que poseen actividad proteasa y polinucleotidos que los codifican.
WO2010133668A3 (en) Eukaryotic host cell comprising an expression enhancer
MX2014007446A (es) Variantes de subtilasa y polinucleotidos que las codifican.
WO2010028093A3 (en) Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells